Portal de Periódicos da CAPES

Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses — New Vaccine Surveillance Network, United States, 2016–2021

2022; Centers for Disease Control and Prevention; Volume: 71; Issue: 40 Linguagem: Inglês

10.15585/mmwr.mm7140a1

1545-861X

Ariana Perez, Joana Y Lively, Aaron T. Curns, Geoffrey A. Weinberg, Natasha Halasa, Mary Allen Staat, Peter G. Szilagyi, Laura S Stewart, Monica McNeal, Benjamin R Clopper, Yingtao Zhou, Brett Whitaker, Elizabeth LeMasters, Elizabeth Harker, Janet A. Englund, Eileen J. Klein, Rangaraj Selvarangan, Christopher J. Harrison, Julie A. Boom, Leila C. Sahni, Marian G. Michaels, John V. Williams, Gayle Langley, Susan I. Gerber, Angela P. Campbell, Aron J. Hall, Brian Rha, Meredith McMorrow, Bonnie Strelitz, Karine Lacombe, Mary E. Moffatt, Jennifer E. Schuster, Chelsea Rohlfs, Miranda Howard, Yesenia Romero, James D. Chappell, Pedro A. Piedra, Vasanthi Avadhanula, Wende Fregoe, Christina Albertin, Robert H. Hickey, Judith M. Martin,

Emergency and Acute Care Studies

The New Vaccine Surveillance Network (NVSN) is a prospective, active, population-based surveillance platform that enrolls children with acute respiratory illnesses (ARIs) at seven pediatric medical centers. ARIs are caused by respiratory viruses including influenza virus, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza viruses (HPIVs), and most recently SARS-CoV-2 (the virus that causes COVID-19), which result in morbidity among infants and young children (1-6). NVSN estimates the incidence of pathogen-specific pediatric ARIs and collects clinical data (e.g., underlying medical conditions and vaccination status) to assess risk factors for severe disease and calculate influenza and COVID-19 vaccine effectiveness. Current NVSN inpatient (i.e., hospital) surveillance began in 2015, expanded to emergency departments (EDs) in 2016, and to outpatient clinics in 2018. This report describes demographic characteristics of enrolled children who received care in these settings, and yearly circulation of influenza, RSV, HMPV, HPIV1-3, adenovirus, human rhinovirus and enterovirus (RV/EV),* and SARS-CoV-2 during December 2016-August 2021. Among 90,085 eligible infants, children, and adolescents (children) aged <18 years